Autor: |
Ruth, Jason R., Pant, Dhruv K., Pan, Tien-chi, Seidel, Hans E., Baksh, Sanjeethan C., Keister, Blaine A., Singh, Rita, Sterner, Christopher J., Bakewell, Suzanne J., Moody, Susan E., Belka, George K., Chodosh, Lewis A. |
Rok vydání: |
2021 |
Předmět: |
|
DOI: |
10.6084/m9.figshare.14737041.v1 |
Popis: |
Additional file 7: Figure S5. HER2/neu-Prim1 residual disease is enriched for mesenchymal tumor cells. (a-c) IF staining for Hoechst 33258 (blue) and H2B-eGFP (green) along with luminal epithelial marker CK8 (red, top) or myoepithelial marker CK14 (red, bottom), on sections of H2B-eGFP-labeled orthotopic HER2/neu-Prim1 (a) or Wnt1-Prim1 (b) primary tumor (left), residual lesion 28 d after doxycycline withdrawal (right), or normal mammary gland (c). (d-g) Flow cytometry for CD49e vs. CD24 (d, e) or PDGFR-β vs. CD24 (f, g) on H2B-eGFP+DAPI- tumor cells from orthotopic H2B-eGFP-labeled orthotopic HER2/neu-Prim1 primary tumors (d, f) or MRLs (e, g). Scale bars 200 μm for all images. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|